Fletcher H P, Wannarka G L, Sandage B W
Res Commun Chem Pathol Pharmacol. 1982 Mar;35(3):377-88.
Sympathomimetics are extensively used clinically as decongestants and bronchodilators in cough, cold, and sinus remedies. However, few studies have addressed the glycemic potentials of these drugs. In this study, the glycemic potentials of pseudoephedrine (PSD), ephedrine (EPD), and phenyl-propanolamine (PPA), the three most commonly used sympathomimetics, were evaluated. PSD caused a dose-dependent delayed hyperglycemia. This was attenuated when procedural stress was reduced. EPD and PPA did not increase the hyperglycemia due to procedural stress. EPD and PPA blunted the hyperglycemia in fed mice after a 2 g/kg oral glucose challenge; PSD had no effect. The effects of PPA and EPD on post-challenge glucose levels may be partially explained by increased insulin/glucose ratios at 15 minutes post-challenge. These studies indicate that there are differences in the glycemic effects among the sympathomimetics in stressed mice.
拟交感神经药在临床上被广泛用作咳嗽、感冒和鼻窦疾病治疗药物中的减充血剂和支气管扩张剂。然而，很少有研究探讨这些药物对血糖的影响。在本研究中，评估了三种最常用的拟交感神经药伪麻黄碱（PSD）、麻黄碱（EPD）和苯丙醇胺（PPA）对血糖的影响。PSD引起剂量依赖性延迟高血糖。当程序应激减轻时，这种情况会减弱。EPD和PPA不会因程序应激而增加高血糖。在给予2 g/kg口服葡萄糖激发后，EPD和PPA可减轻喂食小鼠的高血糖；PSD则无此作用。PPA和EPD对激发后血糖水平的影响可能部分归因于激发后15分钟时胰岛素/葡萄糖比值的增加。这些研究表明，应激小鼠中拟交感神经药的血糖效应存在差异。
